Boston Scientific Corporation (NYSE: BSX) is listed as one of the 14 Stocks That Will Double in the Next 5 Years. Piper Sandler reaffirmed its Overweight rating and $115 price target on BSX on September 25, 2025, citing confidence in the CHAMPION-AF study as a growth driver for its Watchman device. Despite turbulence from investor concerns about cardiology performance in Q3, Boston Scientific has shown strong sales growth of 21.4% over the past year. The company develops, manufactures, and distributes medical devices globally through its MedSurg and Cardiovascular segments. While BSX is a promising investment, other AI stocks may offer greater upside potential.

Read more at Yahoo Finance: Piper Sandler Reaffirms its Overweight Rating and $115 Price Target on Boston Scientific Corporation (BSX)